SCHEMBL24852534

SCHEMBL24852534

COC(=O)c1ccc(-c2nc(Nc3cnn(C4CCN(S(C)(=O)=O)CC4)c3)ncc2C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 8/20 0.52
▸ JAK2 O60674 4/20 0.44
▸ JAK1 P23458 2/20 0.44
▸ JAK3 P52333 2/20 0.44
▸ MAPT P10636 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ CDK1 P06493 4/20 0.43
▸ CDK2 P24941 4/20 0.43
▸ CCNB1 P14635 3/20 0.43
▸ CCNE1 P24864 3/20 0.43
▸ CDK4 P11802 2/20 0.43
▸ CCND1 P24385 2/20 0.43
▸ CCND3 P30281 2/20 0.43
▸ CDK6 Q00534 2/20 0.43
▸ TYK2 P29597 2/20 0.42
▸ CDK8 P49336 1/20 0.42
▸ CDK7 P50613 1/20 0.42
▸ CDK9 P50750 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ FLT4 P35916 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22098048 0.92 IGF1R (0.54) IGF1RJAK2JAK1JAK3CDK1
SCHEMBL24852530 0.90 IGF1R (0.46) IGF1RJAK2JAK1JAK3TYK2
SCHEMBL24853210 0.90 IGF1R (0.51) IGF1RJAK2JAK1JAK3FLT4
SCHEMBL24852545 0.90 MERTK (0.47) IGF1RJAK2JAK1JAK3CDK2
SCHEMBL24853374 0.87 IGF1R (0.49) IGF1RJAK2JAK1JAK3CDK1
SCHEMBL27059237 0.86 JAK3 (0.55) JAK2JAK1JAK3TYK2
SCHEMBL22097956 0.86 NUAK1 (0.48) IGF1RJAK2JAK1JAK3CDK4
SCHEMBL24853381 0.86 IGF1R (0.44) IGF1RJAK2JAK1JAK3TYK2
SCHEMBL24853511 0.86 IGF1R (0.48) IGF1RJAK2JAK1JAK3CDK1
Hydrochloric Acid SCHEMBL31557685 0.85 NUAK1 (0.47) IGF1RJAK2JAK1JAK3CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-07-09 — — US disclosed
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-07-09 — — US disclosed
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-01-25 — — US disclosed
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-01-25 — — US disclosed
US-20230002362-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof JAK2, JAK1, JAK3 IGF1R 2899/4885JAK2 1/4885JAK1 2/4885
US-20230002362-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF JAK1, JAK3, JAK2 IGF1R 3026/4885JAK2 3/4885JAK1 1/4885
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF JAK2, JAK1, JAK3 IGF1R 2899/4885JAK2 1/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback